High quality specific ChIP-validated antibodies
![](/46/pdcnewsitem/03/78/86/porvairpr436-image.jpg)
The company now offeres the first nine antibodies in its Validated Antibody programme which are H3, RNA pol II (S), RNA pol II (S5), H3K9me3, 5mC, AcH3, AcH4, AR and Sin3a
Chromatrap, a business unit of Porvair Sciences, has launched its own range of Chromatin Immunoprecipitation (ChIP)-validated antibodies.
Building on the company’s success in the solid-state ChIP market, which underpins modern epigenetic research, the addition of ChIP-validated antibodies further enhances the high performance application solutions that Chromatrap can provide researchers.
Chromatrap Product Development Manager, Dr Amy Beynon commented: “The use of high quality and specific ChIP-validated antibodies is essential for the success of a ChIP assay. The antibody must recognise and bind to native protein that is bound to DNA. Antibodies from other applications do not always work well in ChIP. That is why our team has thoroughly investigated the top ten most referenced antibodies in recent epigenetic research papers.” She added “We are pleased to be able to offer these top quality validated antibodies to our customers alongside our expanding range of kits for ChIP assays of every type. This will give our customers confidence in their protocols and their results, safe in the knowledge that a ChIP-validated antibody was at the heart of their assay.”
Chromatrap currently offers a range of ChIP kits for qPCR or sequencing and has now launched the first nine antibodies in its Validated Antibody programme which are H3, RNA pol II (S), RNA pol II (S5), H3K9me3, 5mC, AcH3, AcH4, AR and Sin3a.
Dr Beynon continued: “It is our intention to expand the range as we continue to identify, source and validate antibodies for ChIP experimental use. We hope to have most of the major epigenetic marks validated over the next 12 months.”
Chromatrap validated antibodies are available in 100 uL aliquots at a concentration of 1 mg/ml, delivered overnight from the company’s Wrexham, UK facility to customers worldwide.
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance